Medication Safety Officers Society
3826 Members Strong A society of healthcare professionals dedicated to improving medication safety in healthcare organizations
Two questions related to reactions to carboplatin.
1. Are there any facilities or sites noticing an increase in reports of adverse drug reactions between brands of carboplatin? With the current carboplatin shortage, there is a perception with some of our infusion centers that the Teva product may be resulting in an increase in ADRs for patients.